An analysis of over 160,000 non-valvular atrial fibrillation patients has found that Eliquis, a direct oralanticoagulant or DOAC, had lower rates of major bleeding and stroke/systemic embolism in a series of head-to-head comparisons among Eliquis, Pradaxa, and Xarelto.
Eliquis has a 17% lower rate of stroke/systemic embolism and a 46% lower rate of major bleeding compared with Xarelto. Eliquis has a 31% lower rate of stroke/systemic embolism and a 23% lower rate of major bleeding compared with Pradaxa.
There is a significant safety advantage that DOAC’s like Eliquis have over warfarin, especially in regards to intracranial bleeding.
